NASDAQ:CERE Cerevel Therapeutics (CERE) Stock Price, News & Analysis → The #1 Crypto for AI (From Weiss Ratings) (Ad) Free CERE Stock Alerts $42.55 -0.04 (-0.09%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$42.54▼$42.7950-Day Range$41.00▼$42.7552-Week Range$19.59▼$43.59Volume912,342 shsAverage Volume1.07 million shsMarket Capitalization$7.73 billionP/E RatioN/ADividend YieldN/APrice Target$41.40 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestSocial Media Get Cerevel Therapeutics alerts: Email Address Cerevel Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.20 Rating ScoreUpside/Downside0.3% Upside$42.67 Price TargetShort InterestHealthy9.10% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.24Based on 2 Articles This WeekInsider TradingSelling Shares$4.30 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.72) to ($2.93) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.22 out of 5 starsMedical Sector5305th out of 5,424 stocksPharmaceutical Preparations Industry2509th out of 2,550 stocks 1.1 Analyst's Opinion Consensus RatingCerevel Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.11, and is based on 1 buy rating, 8 hold ratings, and no sell ratings.Amount of Analyst CoverageCerevel Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted9.10% of the float of Cerevel Therapeutics has been sold short.Short Interest Ratio / Days to CoverCerevel Therapeutics has a short interest ratio ("days to cover") of 5.7.Change versus previous monthShort interest in Cerevel Therapeutics has recently decreased by 17.67%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCerevel Therapeutics does not currently pay a dividend.Dividend GrowthCerevel Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CERE. Previous Next 1.2 News and Social Media Coverage News SentimentCerevel Therapeutics has a news sentiment score of 0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Cerevel Therapeutics this week, compared to 3 articles on an average week.MarketBeat FollowsOnly 1 people have added Cerevel Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cerevel Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,302,367.00 in company stock.Percentage Held by InsidersOnly 5.10% of the stock of Cerevel Therapeutics is held by insiders.Percentage Held by Institutions87.73% of the stock of Cerevel Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Cerevel Therapeutics are expected to decrease in the coming year, from ($2.72) to ($2.93) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cerevel Therapeutics is -17.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cerevel Therapeutics is -17.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCerevel Therapeutics has a P/B Ratio of 11.47. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsThe asset beating inflation by 4x"Trump Loophole" Beats Inflation? Inflation has been out of control for years. Forcing you to work longer and harder for more money that is worth less. By using the "Trump Loophole", you can use a special retirement account to buy gold — and other precious metals — without taxes or penalties.That's why we have released our Free Precious Metals Investment Guide that explains all the details About Cerevel Therapeutics Stock (NASDAQ:CERE)Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts.Read More CERE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CERE Stock News HeadlinesMay 4, 2024 | americanbankingnews.comCerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Receives Average Rating of "Hold" from BrokeragesApril 30, 2024 | finance.yahoo.comAddex stock tanks after lead drug flops in Phase II epilepsy trialMay 4, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.April 26, 2024 | finance.yahoo.comTop 20 biopharma kick off 9.6% market cap surge in Q1 2024 amid Medicare price talksApril 22, 2024 | markets.businessinsider.comHold Rating Maintained for Cerevel Post-Positive Phase 3 Data Amid Pending AbbVie AcquisitionApril 18, 2024 | benzinga.comSoon To Be Acquired Cerevel Therapeutics Reveals High Level Data From Late-Stage Parkinson's Disease StudyApril 18, 2024 | msn.comAbbVie buyout Cerevel posts late-stage win for Parkinson’s disease drugApril 18, 2024 | reuters.comCerevel Therapeutics' Parkinson's disease drug meets main goal in late-stage studyMay 4, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.April 18, 2024 | finance.yahoo.comCerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s DiseaseApril 18, 2024 | globenewswire.comCerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson's DiseaseApril 16, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Bioxcel Therapeutics (BTAI) and Unity Biotechnology (UBX)April 12, 2024 | seekingalpha.comAbbVie: Despite The Run, Shares Still Look Attractive, Yielding 3.67%April 5, 2024 | investing.comCerevel Therapeutics director sells $2.12m in stock, buys $175k worthApril 3, 2024 | uk.finance.yahoo.comDirector N Coles Sells 50,000 Shares of Cerevel Therapeutics Holdings Inc (CERE)March 29, 2024 | wsj.comCerevel Therapeutics Holdings Inc.March 29, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP) and Apellis Pharmaceuticals (APLS)March 16, 2024 | finance.yahoo.comCERE Apr 2024 40.000 callMarch 7, 2024 | markets.businessinsider.comCerevel Therapeutics: Hold Rating Amidst Pending AbbVie AcquisitionMarch 6, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX) and Perspective Therapeutics (CATX)March 6, 2024 | seekingalpha.comCerevel Therapeutics: Parkinson's Could Be The IssueFebruary 28, 2024 | markets.businessinsider.comMaintaining Hold Rating Amid ABBV-CERE Deal Progress and Rising Operational CostsFebruary 24, 2024 | uk.finance.yahoo.comABBV Mar 2024 182.500 callFebruary 23, 2024 | bloomberg.comUS Politicians Raise Concerns Over Capital One-Discover DealFebruary 23, 2024 | uk.finance.yahoo.com3M Healthcare Unit Solventum Joins $53 Billion US Corporate Bond Sales SpreeFebruary 22, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Intra-Cellular Therapies (ITCI)February 22, 2024 | finance.yahoo.comAbbVie Selling $15 Billion Bonds to Buy ImmunoGen, CerevelSee More Headlines Receive CERE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cerevel Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/01/2023Today5/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryCoal & Consumable Fuels Current SymbolNASDAQ:CERE CUSIP15677310 CIK767884 Webceres.net Phone844-304-2048FaxN/AEmployees334Year FoundedN/APrice Target and Rating Average Stock Price Target$42.67 High Stock Price Target$45.00 Low Stock Price Target$31.00 Potential Upside/Downside-2.7%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($2.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-432,840,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-100.14% Return on Assets-44.51% Debt Debt-to-Equity Ratio0.50 Current Ratio10.92 Quick Ratio10.92 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.71 per share Price / Book11.47Miscellaneous Outstanding Shares181,580,000Free Float172,316,000Market Cap$7.73 billion OptionableOptionable Beta1.46 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. N. Anthony Coles Jr. (Age 64)M.P.H., Executive Chairman Comp: $1.14MMr. Mark Bodenrader (Age 51)VP of Finance & Chief Accounting Officer Comp: $496.17kDr. John J. Renger Ph.D. (Age 55)Chief Scientific Officer Comp: $779.75kDr. Ramiro Sanchez M.D. (Age 63)Chief Medical Officer Comp: $805.13kMr. Ronald C. Renaud Jr. (Age 55)M.B.A., President, CEO & Director Dr. Susan Altschuller M.B.A. (Age 42)Ph.D., Chief Financial Officer Mr. Matthew CalistriVice President of Investor RelationsMr. Scott M. Akamine J.D. (Age 39)Chief Legal Officer & Corporate Secretary Comp: $444.74kMr. Kenneth A. DiPietro (Age 65)Chief Human Resources Officer Ms. Kathleen Tregoning M.A. (Age 53)Chief Corporate Affairs Officer Comp: $600.79kMore ExecutivesKey CompetitorsLegend BiotechNASDAQ:LEGNAscendis Pharma A/SNASDAQ:ASNDJazz PharmaceuticalsNASDAQ:JAZZIntra-Cellular TherapiesNASDAQ:ITCIViking TherapeuticsNASDAQ:VKTXView All CompetitorsInsiders & InstitutionsTokio Marine Asset Management Co. Ltd.Bought 387,800 shares on 5/2/2024Ownership: 0.214%Mirae Asset Global Investments Co. Ltd.Sold 4,837 shares on 5/1/2024Ownership: 0.017%Simplex Trading LLCBought 4,900 shares on 4/25/2024Ownership: 0.000%Kapitalo Investimentos LtdaBought 180,000 shares on 3/29/2024Ownership: 0.099%PNC Financial Services Group Inc.Sold 3,006 shares on 3/22/2024Ownership: 0.004%View All Insider TransactionsView All Institutional Transactions CERE Stock Analysis - Frequently Asked Questions Should I buy or sell Cerevel Therapeutics stock right now? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cerevel Therapeutics in the last twelve months. There are currently 8 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" CERE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CERE, but not buy additional shares or sell existing shares. View CERE analyst ratings or view top-rated stocks. What is Cerevel Therapeutics' stock price target for 2024? 9 Wall Street analysts have issued 1 year price targets for Cerevel Therapeutics' stock. Their CERE share price targets range from $31.00 to $45.00. On average, they predict the company's share price to reach $42.67 in the next twelve months. This suggests a possible upside of 0.3% from the stock's current price. View analysts price targets for CERE or view top-rated stocks among Wall Street analysts. How have CERE shares performed in 2024? Cerevel Therapeutics' stock was trading at $42.40 on January 1st, 2024. Since then, CERE stock has increased by 0.4% and is now trading at $42.55. View the best growth stocks for 2024 here. Are investors shorting Cerevel Therapeutics? Cerevel Therapeutics saw a drop in short interest in the month of April. As of April 15th, there was short interest totaling 7,920,000 shares, a drop of 17.7% from the March 31st total of 9,620,000 shares. Based on an average trading volume of 1,400,000 shares, the short-interest ratio is currently 5.7 days. Currently, 9.1% of the company's shares are short sold. View Cerevel Therapeutics' Short Interest. How were Cerevel Therapeutics' earnings last quarter? Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) announced its earnings results on Wednesday, November, 1st. The biotechnology company reported ($0.61) EPS for the quarter, topping analysts' consensus estimates of ($0.63) by $0.02. During the same period in the prior year, the company posted ($0.66) earnings per share. What ETFs hold Cerevel Therapeutics' stock? ETFs with the largest weight of Cerevel Therapeutics (NASDAQ:CERE) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO), iShares Neuroscience and Healthcare ETF (IBRN), First Trust Merger Arbitrage ETF (MARB), IQ Merger Arbitrage ETF (MNA), AltShares Event-Driven ET (EVNT), AltShares Merger Arbitrage ETF (ARB), ProShares Merger ETF (MRGR) and Principal Healthcare Innovators ETF (BTEC). What other stocks do shareholders of Cerevel Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cerevel Therapeutics investors own include Precigen (PGEN), Arena Pharmaceuticals (ARNA), CTI BioPharma (CTIC), Achillion Pharmaceuticals (ACHN), Alpha Natural Resources (ANRZQ), Cenveo (CVO), Hess (HES), Palatin Technologies (PTN), Aeterna Zentaris (AEZS) and Avid Bioservices (CDMO). Who are Cerevel Therapeutics' major shareholders? Cerevel Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Tokio Marine Asset Management Co. Ltd. (0.21%), Mirae Asset Global Investments Co. Ltd. (0.02%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Abraham Ceesay, Bain Capital Investors Llc, Deval L Patrick, Gabrielle Sulzberger, John Renger, Kenneth Dipietro, Marijn E Dekkers, Mark Bodenrader, N Anthony Coles, Paul D Burgess, Perceptive Advisors Llc, Ramiro Sanchez, Ronald C Renaud Jr, Scott Akamine and Susan Altschuller. View institutional ownership trends. How do I buy shares of Cerevel Therapeutics? Shares of CERE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CERE) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchCould Your Accounts Be Frozen?Allegiance GoldThe Gold Grab of the CenturyColonial MetalsStock-Picking AI Predicts #1 Stock of 2024AltimetryThe only AI company you should be looking atBehind the MarketsThe A.I. story nobody is telling you (Read ASAP)TradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cerevel Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
